Women's Ischemia Trial (WARRIOR)

Condition: Ischemia (inadequate blood flow to an organ), chest pain

Eligibility

Key Inclusion Criteria:

  • Have signs and symptoms of chest pain that prompted further evaluation by either a heart angiogram or a scan of the heart (coronary CT angiogram) within the previous 3 years  
  • 18 years of age or older
  • Non-obstructive coronary artery disease or have been told that heart arteries are not blocked or have blockages that are less than 50%

Key Exclusion Criteria:

  • Documented acute coronary syndrome within previous 30 days
  • History of non-ischemic dilated or hypertrophic cardiomyopathy
  • Stroke within 180 days
  • End-stage renal disease or on dialysis
  • Intolerance to medications such as statin 
  • Pregnancy
Full Study Name

Study Site - Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR) (IRB no. 53860)

Summary

This study is designed to determine whether intensive medical therapy provided as part of the study is better than usual care in women who have chest pain but who have been told they have no significant blockages of their coronary arteries.

Each woman will be randomized (randomly assigned to a study group) to remain on her current medications as prescribed by her doctor, or to optimal medical therapy which includes aspirin, statin, and blood pressure medications. Women randomized to the optimal therapy group will be provided medications at no cost. Research visits will occur over a three-year period and will include lab assessments and lifestyle questionnaires. Parking will be validated, and a $25 compensation will be given upon the completion of each study visit.

Phase

Phase IV

Principal Investigator

Chrisandra Shufelt, MD, MS

Contact

Jihye (Sophie) Yoo
Phone: 424-315-4306
Email: jihye.yoo@cshs.org

WARRIOR Trial

C. Noel Bairey Merz, MD, talks about a new clinical trial that's underway to learn more about angina and close in on the current knowledge gap about it. 

More information can be found by watching the video from Dr. Bairey Merz, or by emailing the trial coordinator, Michael Elliott at michael.elliott@cshs.org.